# To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects

> **NCT06022354** · PHASE1 · COMPLETED · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** SIM0278 Injection/Placebo

## Key facts

- **NCT ID:** NCT06022354
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-23
- **Primary completion:** 2025-03-18
- **Final completion:** 2025-07-22
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06022354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06022354, "To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06022354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*